Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer
Executive Summary
With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.
You may also be interested in...
Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology
AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.
OBI Pharma To Forge Ahead With Cancer Vaccine In Face Of Study Failure
Taiwanese biotech OBI Pharma plans to plough on with a Phase III study of its investigational cancer vaccine OBI-822/821, despite it failing to meet the primary endpoint in a Phase II/III study. The firm's share price fell by from TWD681 to close at TWD613 on Feb. 22 and slipped a further 9.95% to close at TWD522 on Feb. 23 on Taiwan's GreTai Securities Market following the news.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.